MSFT 429.615 -0.3167% AAPL 240.32 0.3047% NVDA 139.4 0.5554% GOOGL 171.825 0.1953% GOOG 173.39 0.237% AMZN 211.2705 0.266% META 594.855 0.3416% AVGO 167.49 0.5886% TSLA 354.0867 -0.841% TSM 195.79 0.715% LLY 809.885 1.2609% V 313.24 -1.0769% JPM 247.365 0.4528% UNH 606.6797 -0.3024% NVO 110.44 1.6288% WMT 92.555 -0.0918% LVMUY 127.67 0.1333% XOM 117.962 0.095% LVMHF 640.0 -0.039% MA 528.05 -0.6229%
Last update at 2024-12-03T16:49:00Z
AI Leaders Broadcom And SentinelOne Lead 5 Stocks Near Buy Points
Mon 21 Oct 24, 06:24 PMIntuitive Surgical Third Quarter 2024 Earnings: Beats Expectations
Sat 19 Oct 24, 12:12 PMIntuitive Surgical price target raised to $525 from $475 at Stifel
Sat 19 Oct 24, 11:52 AMCompared to Estimates, Intuitive Surgical (ISRG) Q3 Earnings: A Look at Key Metrics
Fri 18 Oct 24, 11:30 PMIntuitive Surgical (ISRG): Financial Growth Fueled by AI-Driven Da Vinci Systems
Fri 18 Oct 24, 07:26 PMIntuitive Surgical Surges 9% on Strong Q3 Results and Regulatory Wins
Fri 18 Oct 24, 04:48 PMQ3 2024 Intuitive Surgical Inc Earnings Call
Fri 18 Oct 24, 11:16 AMIntuitive Surgical, Inc. (ISRG) Beats Q3 Earnings and Revenue Estimates
Thu 17 Oct 24, 09:15 PMWill Intuitive Surgical (ISRG) Beat Estimates Again in Its Next Earnings Report?
Wed 16 Oct 24, 04:10 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 1606.80M | 1890.30M | 1207.00M | 1502.20M | 1279.50M |
| Minority interest | -22.10000M | -23.50000M | 6.20M | 2.50M | -2.90000M |
| Net income | 1322.30M | 1704.60M | 1060.60M | 1379.30M | 1127.90M |
| Selling general administrative | 1739.90M | 1466.50M | 1216.00M | 1178.40M | 986.60M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 4196.00M | 3958.50M | 2861.20M | 3110.20M | 2604.10M |
| Reconciled depreciation | 365.80M | 310.20M | 276.20M | 203.00M | 122.80M |
| Ebit | 1211.30M | 1510.80M | 773.60M | 1171.50M | 1076.60M |
| Ebitda | 1577.10M | 1821.00M | 1049.80M | 1374.50M | 1199.40M |
| Depreciation and amortization | 365.80M | 310.20M | 276.20M | 203.00M | 122.80M |
| Non operating income net other | 29.70M | 69.30M | 157.20M | 127.70M | 80.10M |
| Operating income | 1211.30M | 1821.00M | 773.60M | 1374.50M | 1199.40M |
| Other operating expenses | 4645.10M | 3889.10M | 3308.60M | 3104.00M | 2524.80M |
| Interest expense | 29.70M | 356.00M | 427.20M | 328.20M | 0.00000M |
| Tax provision | 262.40M | 162.20M | 140.20M | 120.40M | 154.50M |
| Interest income | 29.70M | 69.30M | 157.20M | 127.70M | 80.10M |
| Net interest income | 29.70M | 69.30M | 157.20M | 127.70M | 80.10M |
| Extraordinary items | - | - | - | - | -0.50000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 262.40M | 162.20M | 140.20M | 120.40M | 154.50M |
| Total revenue | 6222.20M | 5710.10M | 4358.40M | 4478.50M | 3724.20M |
| Total operating expenses | 2618.90M | 2137.50M | 1811.40M | 1735.70M | 1404.70M |
| Cost of revenue | 2026.20M | 1751.60M | 1497.20M | 1368.30M | 1120.10M |
| Total other income expense net | 395.50M | 69.30M | 433.40M | 127.70M | 80.10M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1344.40M | 1728.10M | 1066.80M | 1381.80M | 1125.00M |
| Net income applicable to common shares | 1322.30M | 1704.60M | 1060.60M | 1379.30M | 1127.90M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 15441.50M | 12974.00M | 13555.00M | 11168.90M | 9733.20M |
| Intangible assets | 636.70M | 49.80M | 70.50M | 77.40M | 112.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 176.70M | 164.30M | 271.10M | 267.50M | 200.20M |
| Total liab | 2044.20M | 1861.40M | 1603.50M | 1409.80M | 1448.50M |
| Total stockholder equity | 13307.60M | 11112.60M | 11951.50M | 9759.10M | 8284.70M |
| Deferred long term liab | - | 72.30M | 71.80M | 53.10M | 51.50M |
| Other current liab | 998.60M | 1276.10M | 1068.30M | 945.80M | 568.90M |
| Common stock | 0.40M | 0.40M | 0.40M | 0.10M | 0.10M |
| Capital stock | 0.40M | 0.40M | 0.40M | 0.10M | 0.10M |
| Retained earnings | 4743.00M | 3500.10M | 4760.90M | 3261.30M | 2494.50M |
| Other liab | - | 369.70M | 414.00M | 386.60M | 349.60M |
| Good will | 348.70M | 348.50M | 343.60M | 336.70M | 307.20M |
| Other assets | - | 1183.60M | 13555.00M | 2127.00M | 680.50M |
| Cash | 2750.10M | 1581.20M | 1290.90M | 1622.60M | 1167.60M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1658.70M | 1861.40M | 1603.50M | 1409.80M | 1448.50M |
| Current deferred revenue | 446.10M | 438.30M | 414.00M | 382.40M | 365.20M |
| Net debt | -2660.30000M | -1581.20000M | -1203.90000M | -1622.60000M | -1167.60000M |
| Short term debt | 25.30M | - | - | - | -568.90000M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 89.80M | - | 87.00M | - | - |
| Other stockholder equity | 8576.40M | 7774.60M | 7214.40M | 6472.80M | 5777.70M |
| Property plant equipment | - | 2374.20M | 1876.40M | 1577.30M | 1272.90M |
| Total current assets | 7888.00M | 8576.80M | 9989.30M | 8116.10M | 7511.50M |
| Long term investments | 2120.00M | 2623.60M | 4415.50M | 1757.70M | 2623.50M |
| Net tangible assets | - | 9983.30M | 11607.90M | 8891.20M | 7515.20M |
| Short term investments | 2473.10M | 2541.00M | 2940.00M | 3548.90M | 2054.10M |
| Net receivables | 1267.50M | 942.10M | 782.70M | 645.50M | 645.20M |
| Long term debt | - | - | - | - | - |
| Inventory | 1220.60M | 893.20M | 587.10M | 601.50M | 595.50M |
| Accounts payable | 188.70M | 147.00M | 121.20M | 81.60M | 1083.30M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 70.70M | 50.40M | 27.60M | 20.90M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12.20000M | -162.50000M | -24.20000M | 24.90M | 12.40M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.40M | 0.40M | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 3500.10M | 4760.90M | 3261.30M | 2494.50M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 597.60M | -1613.70000M | -3511.20000M | -986.60000M | -2407.50000M |
| Deferred long term asset charges | - | - | - | - | 425.60M |
| Non current assets total | 7553.50M | 4397.20M | 3565.70M | 3052.80M | 2221.70M |
| Capital lease obligations | - | - | 87.00M | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 1258.90M | 1916.00M | -2099.30000M | -561.40000M | -669.10000M |
| Change to liabilities | - | 216.00M | 235.10M | 3.00M | -117.10000M |
| Total cashflows from investing activities | - | 1370.80M | -2461.50000M | -940.60000M | -1154.40000M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -287.60000M | -2572.30000M | 43.00M | -85.70000M | -168.40000M |
| Change to operating activities | - | 44.00M | -38.40000M | -91.50000M | -47.60000M |
| Net income | 1817.30M | 1344.40M | 1728.10M | 1066.80M | 1381.80M |
| Change in cash | 1169.40M | 294.70M | -332.50000M | 455.90M | 273.20M |
| Begin period cash flow | 1600.70M | 1306.00M | 1638.50M | 1182.60M | 909.40M |
| End period cash flow | 2770.10M | 1600.70M | 1306.00M | 1638.50M | 1182.60M |
| Total cash from operating activities | 1813.80M | 1490.80M | 2089.40M | 1484.80M | 1598.20M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 421.80M | 365.80M | 310.20M | 276.20M | 203.00M |
| Other cashflows from investing activities | - | -12.80000M | -8.70000M | -37.70000M | -59.70000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -712.50000M | -546.60000M | -256.00000M | -170.10000M | -360.50000M |
| Change to account receivables | -186.30000M | -159.30000M | -142.30000M | 5.70M | 38.80M |
| Sale purchase of stock | -416.30000M | -2607.40000M | -211.60000M | -134.30000M | -269.50000M |
| Other cashflows from financing activities | -167.60000M | -198.70000M | -21.90000M | -260.20000M | -171.70000M |
| Change to netincome | - | 324.10M | 386.60M | 453.00M | -327.80000M |
| Capital expenditures | 1064.20M | 532.40M | 353.50M | 341.50M | 425.60M |
| Change receivables | - | -159.30000M | -142.30000M | 5.70M | -38.80000M |
| Cash flows other operating | - | 235.40M | 99.90M | 131.70M | -56.20000M |
| Exchange rate changes | - | - | -3.40000M | -2.60000M | -2.20000M |
| Cash and cash equivalents changes | - | 289.30M | -332.50000M | 455.90M | -2923.20000M |
| Change in working capital | -777.60000M | -619.10000M | -368.10000M | -273.20000M | -321.50000M |
| Stock based compensation | 592.80M | 513.20M | 449.20M | 395.40M | 335.80M |
| Other non cash items | 40.30M | 71.80M | 32.60M | -38.00000M | 7.10M |
| Free cash flow | 749.60M | 958.40M | 1735.90M | 1143.30M | 1172.60M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ISRG Intuitive Surgical Inc |
-6.16 1.13% | 536.69 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-1.34 1.11% | 119.77 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
2.69 1.11% | 244.70 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.14 0.51% | 221.68 | 47.65 | 17.51 | 3.60 | 2.69 | 4.33 | 19.06 |
| HOCPF HOYA Corporation |
- -% | 124.49 | 35.71 | - | 0.06 | 6.34 | 0.05 | 0.15 |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
1020 Kifer Road, Sunnyvale, CA, United States, 94086-5304
| Name | Title | Year Born |
|---|---|---|
| Dr. Gary S. Guthart Ph.D. | Pres, CEO & Director | 1966 |
| Mr. Marshall L. Mohr | Exec. VP of Global Bus. Services | 1956 |
| Mr. David J. Rosa | Exec. VP and Chief Strategy & Growth Officer | 1968 |
| Dr. Myriam J. Curet McAdams F.A.C.S., M.D. | Exec. VP & Chief Medical Officer | 1957 |
| Mr. Robert DeSantis | Exec. VP & Chief Product Officer | 1966 |
| Mr. Jamie E. Samath | Sr. VP & CFO | 1971 |
| Mr. Fredrik Widman | VP, Principal Accounting Officer & Corp. Controller | NA |
| Mr. Philip Kim | Head of Investor Relations | NA |
| Mr. Gary Loeb | Gen. Counsel & Chief Compliance Officer | NA |
| Mr. Julian Nikolchev | Sr. VP of Corp. Devel. & Strategy | 1954 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...